 |
|
Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients With Primary Type Ha or IIb Hyperlipidemia
Michel Farnier, MD, PhD;
Françoise Bonnefous, MSc;
Nathalie Debbas, MD;
Alan Irvine, MD
Arch Intern Med. 1994;154(4):441-449.
Abstract
| |
Background
Few studies have been performed to compare fenofibrate, a second-generation fibrate, and simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. This study was aimed to compare the efficacy of both drugs in reducing atherogenic risk factors in type IIa or IIb hyperlipidemia.
Methods
Sixty-three patients entered this singlecenter, double-blind, crossover trial. Sixty patients (32 with type IIa and 28 with type lib hyperlipidemia) were randomized to treatment for 3 months with a single daily 200-mg dose of micronized fenofibrate or 20 mg of simvastatin and then changed to the alternative treatment for a further 3-month period.
Results
After the first treatment period, in both types IIa and IIb, fenofibrate and simvastatin produced similar significant reductions in levels of total cholesterol and low-density lipoprotein cholesterol; high-density lipoprotein cholesterol levels were increased with both drugs in type IIb. Only fenofibrate decreased total triglyceride levels in type lib, Lp(a) lipoprotein levels in patients with high baseline values, and fibrinogen. After the second period of treatment, in both types IIa and IIb, switching from fenofibrate to simvastatin resulted in a further reduction in total cholesterol and low-density lipoprotein cholesterol levels. The difference in the response of the two treatments on levels of total triglycerides, Lp(a) lipoprotein, and fibrinogen was confirmed after changing over to the alternative treatment. This short-term study showed few adverse effects for both drugs.
Conclusions
Fenofibrate and simvastatin provide similar variations on total cholesterol and low-density lipoprotein cholesterol levels after a 3-month treatment period, with simvastatin having the capacity to decrease these measures further when administered after fenofibrate. However, fenofibrate exhibits a significant effect on other established risk factors, such as total triglyceride, fibrinogen, and Lp(a) lipoprotein levels, and accordingly has a broader spectrum of activity than simvastatin.
(Arch Intern Med. 1994;154:441-449)
Author Affiliations
From Point Médical, Dijon, France (Dr Farnier), and Laboratoires Fournier S.C.A., Daix, France (Ms Bonnefous and Drs Debbas and Irvine).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effectiveness of lipid lowering drugs in general practice: Article illustrates major problem
Wang et al.
BMJ 2003;327:50-51.
FULL TEXT
NALTREXONE EXERTS A FAVOURABLE EFFECT ON PLASMA LIPIDS IN ABSTINENT PATIENTS WITH ALCOHOL DEPENDENCE
Budzynski et al.
Alcohol Alcohol 2000;35:91-97.
ABSTRACT
| FULL TEXT
Forecasting Patient Outcomes in the Management of Hyperlipidemia
Brier et al.
Arch Intern Med 1999;159:569-575.
ABSTRACT
| FULL TEXT
An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
Black et al.
Arch Intern Med 1998;158:577-584.
ABSTRACT
| FULL TEXT
Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia
Guerin et al.
Arterioscler. Thromb. Vasc. Bio. 1996;16:763-772.
ABSTRACT
| FULL TEXT
Effects of Simvastatin on Plasma Lipids and Apolipoproteins in Familial Hypercholesterolemic Swine
Hasler-Rapacz et al.
Arterioscler. Thromb. Vasc. Bio. 1996;16:137-143.
ABSTRACT
| FULL TEXT
|
